Navigation Links
Another clue to how obesity works
Date:10/14/2011

The effects of obesity - both on our bodies and on the health budget - are well known, and now, scientists are getting closer to understanding how the disease progresses, providing clues for future treatments.

In a study, published today in the prestigious journal Cell Metabolism, researchers at Monash University in collaboration with colleagues in the United States, have revealed how resistance to the hormone leptin, a key causal component of obesity, develops.

Lead author Professor Tony Tiganis, of the Monash Obesity and Diabetes Institute and Monash University's Department of Biochemistry and Molecular Biology, said our bodies produce leptin in response to increasing fat deposits.

"Acting on a part of the brain called the hypothalamus, leptin instructs the body to increase energy expenditure and decrease food intake, and so helps us maintain a healthy body weight," said Professor Tiganis.

"The body's response to leptin is diminished in overweight and obese individuals, giving rise to the concept of 'leptin-resistance'. We've discovered more about how 'leptin-resistance' develops, providing new directions for research into possible treatments."

Two proteins are already known to inhibit leptin in the brain and Professor Tiganis' team have discovered a third. In mice, this third protein becomes more abundant with weight-gain, exacerbating leptin-resistance and hastening progression to morbid obesity. The study showed that the three negative regulators of leptin take effect at different stages, shedding light on how obesity progresses.

"Drugs targeting one of the negative regulators are already in clinical trials for Type 2 Diabetes, however, our research shows that in terms of increasing leptin-sensitivity in obesity, targeting only one of these won't be enough. All three regulators might need to be switched off," said Professor Tiganis.

The study showed that high fat diet-induced weight gain is largely prevented in genetically-modified mice when two of the negative regulators are deleted in the brain.

"We now have to determine what happens when all three negative regulators are neutralised. Do we prevent high fat diet-induced obesity?"

Professor Tiganis said the more that is known about obesity, the better equipped scientists are to develop drugs to support good diet and exercise choices.

"Humans have a deep-seated attraction to overeating and nutrient-rich food, inherited from our hunter-gatherer ancestors. Now that food is more readily available and our lifestyles are less active, our evolutionary drive to overeat is becoming problematic."

More than four million Australians are obese and if current trends continue, by 2020, more than 80 per cent of adults and almost one third of children will be overweight or obese. Studies indicate that obesity and related health issues cost Australians more than $56 billion a year.

"Simply telling people to eat less and exercise more is not going to be sufficient to reverse the obesity trend. There is a pressing need to develop novel drugs that complement diet and exercise to both prevent and treat this disease," said Professor Tiganis.


'/>"/>
Contact: Emily Walker
emily.walker@monash.edu
619-903-4844
Monash University
Source:Eurekalert

Related medicine news :

1. As One Life Starts, Another May Be Saved
2. No One Treatment for Acid Reflux Clearly Better Than Another: Study
3. Another Blood Test for Alzheimers Shows Promise
4. FDA Approves Another New Drug to Fight Hepatitis C
5. Study suggests another look at testosterone-prostate cancer link
6. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
7. Tufts biologists find another clue to the origins of degenerative diseases
8. Penn study suggests another avenue for detecting Alzheimers disease
9. Polluted Air Another Danger to U.S. Troops in Iraq
10. Scientists Spot Another Gene Behind Type 2 Diabetes
11. Generic drug may improve the effectiveness of cancer nanotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: